期刊文献+

冠心病患者外周血单核细胞镁浓度对心室重塑的影响 被引量:1

Effects of Magnesium Concentration of Peripheral blood mononuclear cell on ventricular remodeling in patients with coronary artery disease
下载PDF
导出
摘要 目的观察冠心病患者外周血单核细胞镁浓度、血清基质金属蛋白酶-9水平变化及其与心室重塑、心功能的关系。方法选择78例冠心病患者,根据左室射血分数(LVEF)分为3组,1组LVEF>0.50、2组LVEF>0.35、3组LVEF<0.35。测定患者外周血单核细胞内镁(Mg)及血清白细胞介素-6(IL-6)、基质金属蛋白酶-9(MMP-9)水平,超声测定左室收缩末期容量指数(LVESVI)、舒张末期容量指数(LVEDVI)。结果随着LVEF降低,患者血单核细胞Mg降低、血清IL-6及MMP-9显著增高(P<0.05);LVEDVI、LVESVI与Mg均呈负相关(相关系数分别是r=-0.49,r=-0.43;P<0.01),LVEDVI与IL-6、MMP-9呈正相关(相关系数分别是r=0.41,r=0.47;P<0.01);Mg与IL-6及MMP-9均呈负相关(相关系数分别是r=-0.47,r=-0.58;P<0.01)。结论冠心病患者的心肌重塑及收缩功能障碍,可能与细胞内缺镁有关。 Objective To observe the change in peripheral blood intramonocyte ionized magnesium concentration and serum matrix metalloproteinase-9 level and relations between these changes and ventricular remodeling in patients with coronary artery disease (CHD). Methods 78 patients with CHD were randomly into three groups: Left ventricular ejection fraction (LVEF) 〉0.50 in group 1 ; LVEF 〉0.35 in group 2; LVEF 〈 0.35 in group 3. left ventricular end systolic volume index (LVESVI) and left ventricular end diastolic volume index (LVEDVI) were measured by Echo-Doppler, intramonocyte ionized magnesium, serum interleukin -6 and matrix metalloproteinases-9 (MMP-9) level were assayed also. Results With the decreased LVEF, the intramonocyte magnesium decreased, serum interleukin-6 and MMP-9 levels were increased significantly( P 〈 0.05 ), LVEDVI, LVESVI were negative correlation with the intramonocyte magnesium( LVEDVI : r = - 0.49 ; LVESVI : r = - 0. 43 ; P 〈 0.01 ), while LVEDVI was positive correlation with interleukin-6 and MMP-9, respectively ( r = 0. 41,0. 47 ,P 〈0.01 ) ; intramonocyte magnesium was negative correlation with interleukin-6 and MMP-9, respectively ( r = - 0. 47, - 0. 58, P 〈 0.01 ). Conclusion Cardiac remodeling and contractile dysfunction is involved decrease in intramonocyte magnesium in patients with CHD.
出处 《中国分子心脏病学杂志》 CAS 2005年第3期535-537,共3页 Molecular Cardiology of China
关键词 冠状动脉疾病 心力衰竭 心脏功能 细胞因子 基质金属蛋白酶 心室重塑 Coronary artery disease Heart failure Cardiac function Magnesium Cytokine Matrix metalloproteinases
  • 相关文献

参考文献10

  • 1[1]Yue H, Uzui H, Lee JD, et al. Effects of magnesium on matrix metalloproteinase-2 production in cultured rat cardiac fibroblasts.Basic Res Cardiol, 2004, 99:257-263.
  • 2[2]Yue H, Lee JD, Shimizu H, et al. Effects of magnesium on the production of extracellular matrix metalloproteinases in cultured rat vascular smooth muscle cells. Atherosclerosis, 2003, 166:271-277.
  • 3[3]Ueshima K, Shibata M, Suzuki T. Extracellular matrix disturbances in acute myocardial infarction: relation between disease severity and matrix metalloproteinase-1, and effects of magnesium pretreatment on reperfusion injury. Magnes Res, 2003, 16:120-126.
  • 4[4]Schwartzkopff B, Fassbach M, Pelzer B, et al. Elevated plasma markers of collagen degradation in patients with mild to moderate dilated cardiomyopathy. Eur J Heart Fail, 2002, 4:439-444.
  • 5[5]Sakata Y, Yamamoto K, Mano T, et al. Activation of matrix metalloproteinases precedes left ventricular remodeling in hypertensive heart failure rats: its inhibition as a primary effect of Angiotensinconverting enzyme inhibitor. Circulation, 2004,109:2143-2149.
  • 6[6]King MK, Coker ML, Goldberg A, et al. Selective matrix metalloproteinase inhibition with developing heart failure: effects on left ventricular function and structure. Circ Res, 2003, 92:177-185.
  • 7[7]Delva P, Lechi A. Intralymphocyte magnesium decrease in patients with primary aldosteronism. Possible links with cardiac remodelling.Magnes Res, 2003,16:206-209.
  • 8[8]Pages N, Gogly B, Godeau G, et al. Structural alterations of the vascular wall in magnesium- deficient mice. A possible role of gelatinases A (MMP-2) and B (MMP-9). Magnes Res, 2003,16: 43-48.
  • 9[9]Shechter M, Hod H, Rabinowitz B, et al. Long-term outcome of intravenous magnesium therapy in thrombolysis-ineligible acute myocardial infarction patients. Cardiology, 2003, 99: 205-210.
  • 10[10]McCurley JM, Hanlon SU, Wei SK, et al. Furosemide and the progression of left ventricular dysfunction in experimental heart failure.J Am Coll Cardiol, 2004, 44: 1301-1307.

同被引文献7

  • 1Seelig MS. Consequences of magnesium deficiency on the enhancement of stress reactions; preventive and therapeutic implications. J Am Coll Nutr, 1994, 13:429-446.
  • 2Nakaigawa Y, Akazawa S, Shimizu R, et al. Effects of magnesium sulphate on the cardiovascular system, coronary circulation and myocardial metabolism in anaesthetized dogs. Br J Anaesth,1997, 79:363-368.
  • 3Wilkes NJ, Mallett SV, Peachey T, et al. Correction of ionized plasma magnesium during cardiopulmonary bypass reduces the risk of postoperative cardiac arrhythmia. Anesth Analg,2002,95:828-834.
  • 4McCurley JM, Hanlon SU, Wei SK, et al. Furosemide and the progression of left ventricular dysfunction in experimental heart failure. J Am Coll Cardiol, 2004, 44: 1301-1307.
  • 5Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA, 2003, 289:2560-2572.
  • 6Tan LB, Schlosshan D, Barker D. Fiftieth anniversary of aldosterone: from discovery to cardiovascular therapy. Int J Cardiol, 2004, 96: 321-333.
  • 7Endoh M. Magnesium and cardiovascular regulatory factor. Clin Calcium, 2005, 15: 162-174.

引证文献1

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部